The Use of the Cytokines EMAP-II, IL-19 and IL-10 as Biomarkers to Determine Prognosis of Non – Hodgkin’s Lymphoma
Manal Mohamed Saber*
Clinical Pathology Department, Faculty of medicine, Minia University, Egypt
- *Corresponding Author:
- Manal Mohamed Sabre
Clinical Pathology Department
Faculty of Medicine
Minia University, Egypt
E-mail: [email protected]
Received date: May 13, 2016; Accepted date: July 01, 2016; Published date: July 06, 2016
Citation: Saber MM (2016) The Use of the Cytokines EMAP-II, IL-19 and IL-10 as Biomarkers to Determine Prognosis of Non – Hodgkin’s Lymphoma. J Clin Cell Immunol 7:437. doi:10.4172/2155-9899.1000437
Copyright: © 2016 Saber MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Establishing diagnostic and prognostic factors are very important in the management of Non-Hodgkin Lymphoma (NHL). Our aim was to evaluate the clinical significance of serum EMAP-II, IL-19, and IL–10 in NHL patients for assessing treatment response and prognosis of patients.
Methods: Serum EMAP-II, IL-19, and IL-10 levels were measured in the serum of 64 NHL patients before and after treatment with CHOP-based chemotherapy by enzyme-linked immunosorbent assay. Correlations of marker levels to the laboratory, clinicopathological and immunophenotyping markers were performed.
Results: Serum levels of EMAP-II and IL-10 were higher before therapy and decreased significantly thereafter (P<0.001). High EMAP-II and IL-10 were correlated with serum ALT and blood urea respectively (P=0.043, P=0.020). Significantly higher levels of IL-19 were demonstrated in patients with relapse (P<0.001). A significant association was found between serum IL-19 and AST, CD23 and B-cl2 (P=0.032, P=0.015, P=0.024 respectively). There was a significant correlation between EMAP-II and IL-10 in NHL patients (r=0.827, P<0.001).
Conclusion: EMAP-II, IL-19, and IL-10 can all serve as useful diagnostic markers in NHL patients. They assessed response to therapy. IL-19 proved to be the most sensitive predictor of advanced disease and poor prognosis.